Cinhyaluronate sodium

Drug Profile

Cinhyaluronate sodium

Alternative Names: Hyaluronic acid ophthalmic - Seikagaku Corporation; SI-614

Latest Information Update: 09 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seikagaku Corporation
  • Class Eye disorder therapies; Glycosaminoglycans
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Dry eyes

Most Recent Events

  • 02 Feb 2016 Phase-II/III clinical trials in Dry eyes in European Union before February 2016 (Ophthalmic) (Seikagaku Corporation pipeline, July 2016)
  • 02 Feb 2016 Phase II/III development is ongoing in USA (Seikagaku Corporation pipeline, July 2016)
  • 01 Jul 2014 Phase-II/III clinical trials in Dry eyes in USA (Ophthalmic) (NCT02205840)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top